Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03093922
Title A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Chicago Chicago Illinois 60637 United States Details
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge New Jersey 07920 United States Details
Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey 07748 United States Details
Memorial Sloan Kettering Bergen Montvale New Jersey 07645 United States Details
Memorial Sloan Kettering Commack (Limited Protocol Activities) Commack New York 11725 United States Details
Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison New York 10604 United States Details
Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York 10065 United States Details
Memorial Sloan Kettering Nassau (Limited Protocol Activities) Uniondale New York 11553 United States Details
Ohio State University Columbus Ohio 43210 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field